Arvinas Inc
ARVN7.530USD
+0.110+1.48%
收盤 08/04, 16:00（美東）報價延遲15分鐘
549.69M總市值
虧損本益比TTM
關於 Arvinas Inc 公司
Arvinas, Inc. 是一家臨牀階段的生物技術公司。該公司通過其 PROteolysis Targeting Chimera (PROTAC) 蛋白質降解劑平臺，率先開發蛋白質降解療法，旨在利用人體的天然蛋白質處理系統選擇性高效地降解和去除致病蛋白質。該公司正在通過臨牀開發項目推進多種研究藥物，包括 vepdegestrant、ARV-393 和 ARV-102。Vepdegestrant 是一種口服生物可利用的 PROTAC 蛋白質降解劑，旨在靶向和降解 ER，用於治療局部晚期或轉移性 ER+/HER2- 乳腺癌患者。該公司正在與輝瑞共同開發 vepdegestrant。ARV-393 是一種口服生物可利用的 PROTAC，旨在降解 BCL6，這是一種轉錄抑制因子和正常 B 細胞成熟和分化過程的關鍵調節劑。ARV-102 正在開發中，用於治療神經退行性疾病。
公司簡介
公司代碼ARVN
公司名稱Arvinas Inc
上市日期Sep 27, 2018
CEODr. John G. Houston, Ph.D.
員工數量430
證券類型Ordinary Share
年結日Sep 27
公司地址5 Science Park
城市NEW HAVEN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編06511-1966
電話12035351456
網址https://www.arvinas.com/
公司代碼ARVN
上市日期Sep 27, 2018
CEODr. John G. Houston, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
收入明細
FY2025Q1
FY2024
FY2023
暫無數據
地區USD
名稱
營收
佔比
United States
188.80M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 7月27日 週日
更新時間: 7月27日 週日
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
11.44%
BlackRock Institutional Trust Company, N.A.
6.90%
Citadel Advisors LLC
5.31%
T. Rowe Price Associates, Inc.
5.14%
Pfizer Inc
4.74%
Other
66.47%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
11.44%
BlackRock Institutional Trust Company, N.A.
6.90%
Citadel Advisors LLC
5.31%
T. Rowe Price Associates, Inc.
5.14%
Pfizer Inc
4.74%
Other
66.47%
股東類型
持股股東
佔比
Investment Advisor
36.14%
Hedge Fund
24.67%
Investment Advisor/Hedge Fund
17.48%
Venture Capital
6.80%
Corporation
4.74%
Research Firm
3.41%
Individual Investor
2.23%
Sovereign Wealth Fund
1.70%
Pension Fund
0.37%
Other
2.45%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
503
71.52M
97.99%
-18.05M
2025Q1
525
68.48M
93.89%
-22.67M
2024Q4
505
80.31M
116.78%
-4.24M
2024Q3
496
79.95M
116.50%
-140.10K
2024Q2
489
78.26M
114.11%
+1.71M
2024Q1
494
75.44M
110.48%
+3.48M
2023Q4
497
68.16M
100.81%
+12.55M
2023Q3
472
52.04M
94.71%
-3.94M
2023Q2
473
53.77M
100.76%
-3.55M
2023Q1
475
55.60M
104.22%
-4.17M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
8.35M
11.44%
+1.30M
+18.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.04M
6.9%
-246.30K
-4.66%
Mar 31, 2025
Citadel Advisors LLC
3.88M
5.31%
+395.72K
+11.37%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.75M
5.14%
-273.88K
-6.81%
Mar 31, 2025
Pfizer Inc
3.46M
4.74%
--
--
Mar 31, 2025
RTW Investments L.P.
3.33M
4.57%
--
--
Mar 31, 2025
Logos Global Management LP
3.30M
4.52%
+3.30M
--
Jun 10, 2025
Opaleye Management Inc.
1.98M
2.71%
+350.00K
+21.54%
Mar 31, 2025
State Street Global Advisors (US)
1.90M
2.6%
+259.14K
+15.83%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.80M
2.47%
+1.80M
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
1.09%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.77%
Invesco NASDAQ Future Gen 200 ETF
0.46%
Tema Oncology ETF
0.41%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares U.S. Pharmaceuticals ETF
0.25%
Zacks Small/Mid Cap ETF
0.18%
JPMorgan Fundamental Data Science Small Core ETF
0.15%
Tema Neuroscience and Mental Health ETF
0.15%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比1.09%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0.77%
Invesco NASDAQ Future Gen 200 ETF
佔比0.46%
Tema Oncology ETF
佔比0.41%
Federated Hermes MDT Small Cap Core ETF
佔比0.3%
iShares U.S. Pharmaceuticals ETF
佔比0.25%
Zacks Small/Mid Cap ETF
佔比0.18%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.15%
Tema Neuroscience and Mental Health ETF
佔比0.15%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
